Telmisartan is an angiotensin II receptor antagonist that is used primarily in the treatment of hypertension and diabetic nephropathy. It works by selectively blocking the binding of angiotensin II to the AT1 receptors present in vascular smooth muscle and the adrenal glands. By blocking the vasoconstrictor and aldosterone-secreting effects of angiotensin II, telmisartan helps lower blood pressure. It is available under various brand names as an oral medication and has a well-established safety profile supported by long-term clinical trials. Growing awareness about cardiovascular health and increasing prevalence of hypertension can drive the global telmisartan market growth.
Market Dynamics:
Global telmisartan market growth is driven by factors such as rapidly aging population, rising prevalence of hypertension worldwide, increasing adoption of sedentary lifestyle resulting in obesity, and growing healthcare expenditure in emerging nations. However, availability of generic substitutes and patent expiration of major brands can pose challenges for market players. Continuous research on expanding therapeutic applications of telmisartan and ongoing clinical trials evaluating its efficacy in treatment of conditions beyond hypertension can offer opportunities for stakeholders in the near future. Partnerships with local distribution networks in developing countries also provide an attractive avenue for leveraging unmet demand.
Key Features of the Study:
- This report provides in-depth analysis of the global telmisartan market, and provides market size (US$ Billion) and compound annual growth rate (CAGR%) for the forecast period (2024–2031), considering 2023 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global telmisartan market based on the following parameters – company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include, Boehringer Ingelheim GmbH, Glenmark Pharmaceuticals Ltd., Teva Pharmaceutical Industries Ltd., Sandoz International GmbH, Aurobindo Pharma, Sun Pharmaceutical Industries Ltd., Mylan N.V., Cipla Ltd., Abbott Laboratories, Cadila Healthcare Ltd, Torrent Pharmaceuticals Ltd., Merck KGaA, Pfizer Inc., Sanofi S.A., Bayer AG, AstraZeneca PLC, Daiichi Sankyo Company, Limited, Macleods Pharmaceuticals Ltd.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- Global telmisartan market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global telmisartan market
Detailed Segmentation-
- By Composition
- By Indication
- Hypertension
- Nephropathy
- Hepatorenal Syndrome
- Cardiac Arrest
- Stroke
- By Dosage Form
- Tablets
- Capsules
- Injection
- Oral suspension
- By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East
- Africa
- Company Profiles:
- Boehringer Ingelheim GmbH
- Glenmark Pharmaceuticals Ltd.
- Teva Pharmaceutical Industries Ltd.
- Sandoz International GmbH
- Aurobindo Pharma
- Sun Pharmaceutical Industries Ltd.
- Mylan N.V.
- Cipla Ltd.
- Abbott Laboratories
- Cadila Healthcare Ltd
- Torrent Pharmaceuticals Ltd.
- Merck KGaA
- Pfizer Inc.
- Sanofi S.A.
- Bayer AG
- AstraZeneca PLC
- Daiichi Sankyo Company, Limited
- Macleods Pharmaceuticals Ltd.
